Document 3e9wy8vmeJdRKkKZdG4Xnm8o3

\}^vl dx*. < \ > "Tc m |j j r c U r\ iv, 0 ^Cq I_ vita 51 Questions For Consideration With Respect To The Proposed University of Louisville Brain Cancer/VCM Case-Control Study Carlo: Ca-do ha-o l. What is the current status of your relationship with each of the three ^Sfrtdj ^ companies formerly comprising B.F. Goodrich in Louisville? When you met dL(,3_n2jxl,'/> ^MA panel earlier this year you said something about "re- 0 gffr ^ ^establishing a working network with all three companies." u\/erdr Mor^'^r o^ "T^e. w ed coor^-'^ ~Tf 6reor1. 2. What data would you need to get from all three units? Do you anticipate any problems obtaining the necessary data? Are there any other sources of t the necessary data that could be accessed if needed? Answer i* Carlos ft- OtC^ - 21, +Q &JdL. Cat lo ru?C 3. You have described the brain cancer study in terms of "20-year f x follow-up" and "^-year combined retrospective" evaluation. What periods1 of time do these cover?\ How are the data alike and/or different between the M ocCi v ^ c/^ri o two periods of time? \c\ LjQ lc1 itf*' 4. Do you still have the peer reviewers' comments on your 1981 paper on ASL and vinyl chloride? If so, could you make them available to us? This would help us understand how other researchers have viewed the methodology that you employed for that paper and would employ for the brain cancer study. pj o ^ ^03 I'C? * jL^.#cK/^&^tWidh at is your best estimate of the maximun("number of brain cancer cases es O \ju\i, id Afi^^j^tnat could be available for study, assuming 1) that you could only get tissue 'Va<a1~*,a ^ for Goodrich employee cases that were hospitalized in the Louisville area; and 2) that you could get tissue from Goodrich employees hospitalized " V/ .!vl-" * outside the Louisville area as well? This is really a question about what the maximum statistical power of the study is likely to be. 9?r 6. Can we develop a firm timetable for initiation and completion of the study? Co0P*tJricf> c0 eacd-^ c4~ .A Ur TUsZ. i-yAcJl Om-J.'Pfed ' cSu<Jt~ 7. Can we develop line-item breakdowns and prepare a more detailed study ' r \ budget? Udj * G^. Would you consider working with someone like Kenneth Mundt as a co- \ e^rtr, ipo^v p investigator/co-author, to add some additional epidemiologic expertise to the v brain cancer study and to take full advantage of the follow-up data that he ^ will be generating in the industry-wide cohort study? G-'O ! 0--- * ni ^ U < i'T~ ble. AW ^ tOC' .> <I** (K f^lSfc ScJL b?j it< df jOiLs k i-'dtS t~, CMA 121446 Questions For Consideration With Respect To The Proposed University of Louisville Brain Cancer/VCM Case-Control Study Carlo: 1. What is the current status of your relationship with each of the three companies formerly comprising B.F. Goodrich in Louisville? When you met with the CMA panel earlier this year you said something about "re establishing a working network with all three companies." 2. What data would you need to get from all three units? Do you anticipate any problems obtaining the necessary data? Are there any other sources of the necessary data that could be accessed if needed? 3. You have described the brain cancer study in terms of "20-year prospective follow-up" and "25-year combined retrospective" evaluation. What periods of time do these cover? How are the data alike and/or different between the two periods of time? 4. Do you still have the peer reviewers' comments on your 1981 paper on ASL and vinyl chloride? If so, could you make them available to us? This would help us understand how other researchers have viewed the methodology that you employed for that paper and would employ for the brain cancer study. 5. What is your best estimate of the maximum number of brain cancer cases that could be available for study, assuming 1) that you could only get tissue for Goodrich employee cases that were hospitalized in the Louisville area; and 2) that you could get tissue from Goodrich employees hospitalized outside the Louisville area as well? This is really a question about what the maximum statistical power of the study is likely to be. 6. Can we develop a firm timetable for initiation and completion of the study? 7. Can we develop line-item breakdowns and prepare a more detailed study budget? 8. Would you consider working with someone like Kenneth Mundt as a co investigator/co-author, to add some additional epidemiologic expertise to the brain cancer study and to take full advantage of the follow-up data that he will be generating in the industry-wide cohort study? CMA 121447